Candriam S.C.A. Vertex Pharmaceuticals Inc Transaction History

Candriam S.C.A.

$17.1 Billion
Q3 2024

A detailed history of Candriam S.C.A. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Candriam S.C.A. holds 311,307 shares of VRTX stock, worth $146 Million. This represents 0.85% of its overall portfolio holdings.

Number of Shares

311,307

Previous 328,271 5.17%

Holding current value

$146 Million

Previous $154 Million 5.9%

% of portfolio

0.85%

Previous 0.95%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$460.0 - $505.78 $7.8 Million - $8.58 Million	-16,964 Reduced 5.17%	311,307 $145 Million
Q2 2024 Aug 05, 2024	SELL	$392.81 - $485.53 $23.7 Million - $29.3 Million	-60,317 Reduced 15.52%	328,271 $154 Million
Q1 2024 May 03, 2024	BUY	$407.69 - $446.08 $19 Million - $20.7 Million	46,502 Added 13.59%	388,588 $162 Million
Q4 2023 Feb 14, 2024	SELL	$343.0 - $410.68 $14.5 Million - $17.3 Million	-42,245 Reduced 10.99%	342,086 $139 Million
Q3 2023 Nov 13, 2023	SELL	$338.18 - $362.46 $4.14 Million - $4.43 Million	-12,231 Reduced 3.08%	384,331 $134 Million
Q2 2023 Aug 08, 2023	BUY	$314.42 - $351.91 $1.78 Million - $1.99 Million	5,654 Added 1.45%	396,562 $140 Million
Q1 2023 May 12, 2023	SELL	$283.23 - $323.1 $22.2 Million - $25.3 Million	-78,237 Reduced 16.68%	390,908 $123 Million
Q4 2022 Feb 13, 2023	SELL	$285.76 - $321.48 $4.4 Million - $4.95 Million	-15,394 Reduced 3.18%	469,145 $135 Million
Q3 2022 Nov 10, 2022	BUY	$273.83 - $305.53 $4.56 Million - $5.09 Million	16,656 Added 3.56%	484,539 $140 Million
Q2 2022 Aug 03, 2022	SELL	$234.96 - $292.55 $1.5 Million - $1.86 Million	-6,370 Reduced 1.34%	467,883 $132 Million
Q1 2022 May 13, 2022	SELL	$221.42 - $260.97 $37.7 Million - $44.5 Million	-170,379 Reduced 26.43%	474,253 $124 Million
Q4 2021 Feb 10, 2022	BUY	$177.01 - $223.45 $9.17 Million - $11.6 Million	51,803 Added 8.74%	644,632 $142 Million
Q3 2021 Nov 09, 2021	SELL	$181.39 - $202.99 $39 Million - $43.7 Million	-215,038 Reduced 26.62%	592,829 $108 Million
Q2 2021 Jul 20, 2021	BUY	$187.49 - $221.1 $5.31 Million - $6.26 Million	28,321 Added 3.63%	807,867 $163 Million
Q1 2021 Apr 29, 2021	BUY	$207.02 - $241.31 $1,449 - $1,689	7 Added 0.0%	779,546 $177 Million
Q4 2020 Jan 22, 2021	BUY	$207.01 - $276.09 $45.8 Million - $61.1 Million	221,408 Added 39.67%	779,539 $184 Million
Q3 2020 Oct 19, 2020	BUY	$255.65 - $303.1 $3.05 Million - $3.62 Million	11,940 Added 2.19%	558,131 $152 Million
Q2 2020 Jul 23, 2020	SELL	$225.48 - $295.8 $40.4 Million - $53 Million	-179,170 Reduced 24.7%	546,191 $159 Million
Q4 2019 Jan 21, 2020	SELL	$166.71 - $223.91 $34.3 Million - $46 Million	-205,638 Reduced 22.09%	725,361 $159,000
Q3 2019 Oct 21, 2019	SELL	$166.23 - $187.09 $1.58 Million - $1.78 Million	-9,507 Reduced 1.01%	930,999 $158,000
Q2 2019 Aug 01, 2019	BUY	$164.61 - $190.37 $45.9 Million - $53.1 Million	278,986 Added 42.17%	940,506 $172 Million
Q1 2019 May 02, 2019	BUY	$163.73 - $194.7 $4.28 Million - $5.09 Million	26,135 Added 4.11%	661,520 $122 Million
Q4 2018 Feb 14, 2019	BUY	$151.91 - $192.21 $26.9 Million - $34.1 Million	177,234 Added 38.68%	635,385 $105 Million
Q3 2018 Nov 07, 2018	BUY	$167.73 - $192.74 $22 Million - $25.3 Million	131,345 Added 40.19%	458,151 $88.3 Million
Q2 2018 Aug 14, 2018	BUY	$145.72 - $169.96 $3.4 Million - $3.97 Million	23,333 Added 7.69%	326,806 $55.5 Million
Q1 2018 May 09, 2018	SELL	$151.6 - $177.13 $7.93 Million - $9.26 Million	-52,302 Reduced 14.7%	303,473 $49.5 Million
Q4 2017 Feb 07, 2018	SELL	$137.28 - $155.55 $423,783 - $480,182	-3,087 Reduced 0.86%	355,775 $53.3 Million
Q3 2017 Nov 03, 2017	BUY	$148.13 - $162.24 $53.2 Million - $58.2 Million	358,862	358,862 $54.6 Million

Others Institutions Holding VRTX

# of Institutions

1,725

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $120B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account